Loading ...
Sorry, an error occurred while loading the content.

Stakeholder Insight: Hepatitis B & C - Winning Battles But Not The War

Expand Messages
  • Shshonee (Alley)
    Stakeholder Insight: Hepatitis B & C - Winning Battles But Not The War Published: 22 Dec 2004, Publisher: Datamonitor
    Message 1 of 1 , Jan 21, 2005
    • 0 Attachment
      Stakeholder Insight: Hepatitis B & C - Winning Battles But Not The War
      Published: 22 Dec 2004, Publisher: Datamonitor

      http://www.pharmaceutical-business-review.com/research.asp?guid=DMHC2042

      Introduction
      According to the WHO, 350-400 million are chronically infected with HBV and 170-200 million with HCV. Although HBV vaccination and routine screening of donated blood has decreased incidence, the death toll resulting from chronic disease, cirrhosis and HCC is as high as one million per year (WHO, 2002). For HCV related conditions, this number will increase further over the next 10-20 years.

      Scope
      a.. Comprehensive overview of HBV and HCV epidemiology with comment on latest dynamics
      b.. Analysis of drug treatment choice per line therapy per region for both HBV and HCV
      c.. Discussion with key opinion leaders with regard to clinical and non-clinical attributes of therapy
      d.. Future outlook for new HBV and HCV therapies along with unmet needs assessment

      Highlights
      A large majority (60-80%) of the estimated hepatitis B and C patient pool in the 7 major markets are receiving first-line therapy. To increase the treatment pool, manufacturers of hepatitis treatments can either tap into a substantial amount of unidentified cases or meet the needs of non-responder or 'difficult-to-treat' patients.

      Lamivudine dominates first-line therapy for hepatitis B, with adefovir a first switch for resistant virus. This standard sequence is modulated by market cost-sensitivity, HIV co-infection and increasing use of peginterferon monotherapy (20-30%). Datamonitor research has also uncovered off-label use of tenofovir and experimental combinations.

      Increased uptake and aggressive life-cycle management of peginterferons (plus ribavirin) have driven the current standard of care to 73% of first-line choice for HCV. However, the needs of non-responders, genotype 1 and intolerant patients will not be satisfied in the short term.

      Why you should buy this report
      a.. Understand current therapy usage in each region, and the factors driving physician choice
      b.. Compare in-house unmet needs assessment against independent research, to justify future therapy development planning
      c.. Review current head-to-head competition between PEG-Intron and Pegasys per region


      [Non-text portions of this message have been removed]
    Your message has been successfully submitted and would be delivered to recipients shortly.